Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer

Carcinogenesis

Volumn 34, Issue 11, 2013, Pages 2639-2646

  Zhang, Pengnan ^a   Zhang, Pengfei ^b   Zhou, Min ^b   Jiang, Hua ^b   Zhang, Haiyan ^a   Shi, Bizhi ^b   Pan, Xiaorong ^b   Gao, Huiping ^b   Sun, Hong ^a   Li, Zonghai ^b  

^a OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; GELATINASE B; PROTEIN KINASE B; UVOMORULIN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG SENSITIVITY; EXON; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR INVASION; UPREGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84887014104     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt216     Document Type: Article

References (40)

1. Siegel,R et al. (2012) Cancer statistics, 2012. CA Cancer J. Clin., 62, 10-29.
2. Agarwal,R. et al.(2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer, 3, 502-516.
3. Xue,C. et al. (2006) Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res., 66, 192-197.
4. Modjtahedi,H. et al. (2009) Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs, 20, 851-855.
5. Weihua,Z. et al. (2008) Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell, 13, 385-393.
6. Wang,H. et al. (2008) Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. Cancer Lett., 279, 30-38.
7. Bartlett,J.M. et al. (1996) The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer, 73, 301-306.
8. Pines,G. et al. (2010) EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene, 29, 5850-5860.
9. Frederick,L. et al. (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res., 60, 1383-1387.
10. Lynch,T.J. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 350, 2129-2139.
11. Lankiewicz,S. et al.(2008) Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell. Oncol., 30, 463-471.
12. Pines,G. et al. (2010) Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett., 584, 2699-2706.
13. Huang,P.H. et al. (2010) Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Mol. Biosyst., 6, 1227-1237.
14. Antonyak,M.A. et al. (1998) Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem., 273, 2817-2822.
15. Wang,H. et al. (2011) Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia, 13, 461-471.
16. Dubé,P.E. et al. (2012) Epidermal growth factor receptor inhibits colitisassociated cancer in mice. J. Clin. Invest., 122, 2780-2792.
17. Goi,T. et al. (2000) An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity. EMBO J., 19, 623-630.
18. McCawley,L.J. et al. (1998) Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)-mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. J. Cell. Physiol., 176, 255-265.
19. Zeigler,M.E. et al. (1999) Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J. Cell. Physiol., 180, 271-284.
20. Hu,X. et al. (2012) Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch. Gynecol. Obstet., 286, 1537-1543.
21. Mrgineanu,E. et al.(2008) Correlation between E-cadherin abnormal expressions in different types of cancer and the process of metastasis. Rev. Med. Chir. Soc. Med. Nat. Iasi., 112, 432-436.
22. Shi,Z.D. et al. (2011) Heparan sulfate proteoglycans mediate interstitial flow mechanotransduction regulating MMP-13 expression and cell motility via FAK-ERK in 3D collagen. PLoS One, 6, e15956.
23. Conacci-Sorrell,M. et al.(2003) Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. J. Cell Biol., 163, 847-857.
24. Ahmad,N. et al. (2012) Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-ζ pathways. Mol. Cell. Endocrinol., 363, 46-61.
25. Richardson,A. et al.(2005) Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist. Updat., 8, 311-321.
26. Liu,J. et al. (2012) Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression. BMC Cancer, 12, 370.
27. Marchion,D.C. et al. (2011) BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin. Cancer Res., 17, 6356-6366.
28. Schaller,M.D. (2001) Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim. Biophys. Acta, 1540, 1-21.
29. Sanders,M.A. et a. (2000) Collagen IV-dependent ERK activation in human Caco-2 intestinal epithelial cells requires focal adhesion kinase. J. Biol. Chem., 275, 38040-38047.
30. Owen,J.D. et al. (1999) Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol. Cell. Biol., 19, 4806-4818.
31. Sieg,D.J. et al. (2000) FAK integrates growth factor and integrin signals to promote cell migration. Nat. Cell Biol., 2, 249-256.
32. Shibata,K. et al. (1998) Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronectin in ovarian cancer cells. Cancer Res., 58, 900-903.
33. Chambers,S.K. et al. (2012) Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clin. Cancer Res., 18, 2668-2678.
34. Konner,J.A. et al. (2011) Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J. Clin. Oncol., 29, 4662-4668.
35. Brewer,C.A. et al. (2006) Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol. Oncol., 103, 446-450.
36. Brabec,V. et al. (2005) Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updat., 8, 131-146.
37. Bansal,N. et al. (2012) BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J. Gynecol. Oncol., 23, 35-42.
38. Balmanno,K. et al. (2008) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 16, 368-377.
39. Danial,N.N. (2008) BAD: undertaker by night, candyman by day. Oncogene, 27 (suppl. 1), S53-S70.
40. Wang,H. et al. (2012) Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation. FASEB J., 26, 73-80